

**Estimation of the Area-Under-the-Curve of  
Mycophenolic Acid using population  
pharmacokinetic and multi-linear regression  
models simultaneously.**

**Michał J. Figurski & Leslie M. Shaw**

**Biomarker Research Laboratory  
University of Pennsylvania, Philadelphia, PA.**


- ▶ Introduction
  - ▶ The drug and the problem (2 slides)
  - ▶ Concepts of Pharmacokinetics and Therapeutic Drug Monitoring (5 slides)
- ▶ Model development
  - ▶ Overview of the data (1 slide)
  - ▶ Multi-linear regression & population PK models (4 slides)
- ▶ AUC Monitoring Study
  - ▶ Study overview (5 slides)
- ▶ The Script
  - ▶ Snippets of the code (4 slides)
- ▶ Future plans
- ▶ Acknowledgments

# Introduction

The drug: Mycophenolic Acid (MPA)

Slide

3 / 26



**From:**

L.M. Shaw, M. Figurski, M.C. Milone, J. Trofe, R.D. Bloom. *Therapeutic drug monitoring of mycophenolic acid*. Clin J Am Soc Nephrol. 2007, 2(5):1062-72




Exposure?



# Introduction

## The concept of AUC




[http://en.wikipedia.org/wiki/File:Pharmacokinetic\\_parameters.png](http://en.wikipedia.org/wiki/File:Pharmacokinetic_parameters.png)




# Introduction

## The concept of AUC



[http://en.wikipedia.org/wiki/File:Pharmacokinetic\\_parameters.png](http://en.wikipedia.org/wiki/File:Pharmacokinetic_parameters.png)







Predict AUC based on a few, selected time-points.

- ▶ Multiple models in the simple form:

$$AUC = \alpha_0 + \alpha_1 \cdot C_1 + \alpha_2 \cdot C_2 + \alpha_3 \cdot C_3$$

- ▶ Fit by **glm** in a loop, best models selected based on predictive performance
- ▶ Restriction: the same protocol must be followed




From:

M.J. Figurski, A. Nawrocki, M.D. Pescovitz, R. Bouw, L.M. Shaw, *Development of a predictive limited sampling strategy for estimation of mycophenolic acid AUC in patients receiving concomitant Sirolimus or Cyclosporine*. Ther Drug Monit, 2008, 30(4), 445-55.




- ▶ Physiology-based models
- ▶ Form: differential equations, fit by nonlinear mixed effects method
- ▶ **NONMEM** software package is generally used for model development.
- ▶ More flexible than MLR
- ▶ Laborious model development
- ▶ Cost of license



<http://www.openclipart.org/detail/596>

# Model development

Data snippet



### Macro with “proc glm” for developing actual models

```
...  
  
%macro analyze (data=,model=,mod=,name=); *INITIALIZING MACRO ANALYZE**;  
title "Testgroup: &data. Model: &model";  
proc glm data=&data; **START OF PROGRAM THAT I NEED TO RUN ALL TEST GROUPS THROUGH**;  
model auc t = &model; **SPECIFY MODEL WITH MODEL STATEMENT**;  
ODS OUTPUT FitStatistics=fittemp ParameterEstimates=soltemp;  
  
**Store the data in a temporary dataset;  
data fittemp;  
length label $30;  
length group $20;  
length model $15;  
set fittemp;  
label = "&name";  
group = "&data";  
model = "&mod";  
run;  
  
**Add it (stack) to the results dataset;  
data fit;  
set fit fittemp;  
run;  
  
data soltemp;  
length label $30;  
length group $20;  
length model $15;  
set soltemp;  
label = "&name";  
group = "&data";  
model = "&mod";  
  
data solution;  
set solution soltemp;  
run;  
  
%mend analyze;  
  
data fit; **Initialize the dataset, so the 1st row is not lost;  
Run;  
  
...
```

#### Results published in:

M.J. Figurski, A. Nawrocki, M.D. Pescovitz, R. Bouw, L.M. Shaw,  
*Development of a predictive limited sampling strategy for estimation  
of mycophenolic acid AUC in patients receiving concomitant  
Sirolimus or Cyclosporine.* Ther Drug Monit, 2008, 30(4), 445-55



# Model development

## NONMEM Pop-PK model code snippet

**\$PK**

```
GEN = (SEX +1)**THETA(12) ;Gender

BIO = THETA(1)*EXP(ETA(1)) ;Inverse Gaussian absorption model
MAT = THETA(2)*EXP(ETA(2))
CV = THETA(3)*EXP(ETA(3))

V1 = THETA(6)*EXP(ETA(6)) ;Central Volume
CLD = THETA(7)*EXP(ETA(7)) ;Disposition Clearance

IF (TRTI.EQ.0) THEN ;SRL arm
  BIO2 = 0.35*BIO
  MAT2 = THETA(4)*EXP(ETA(4))
  CV2 = THETA(5)*EXP(ETA(5))
  V2 = THETA(8)*EXP(ETA(8)) ;Peripheral Volume
  CLE = THETA(9)*EXP(ETA(9))*GEN ;Elimination Clearance
ELSE ;CsA arm
  BIO2 = 0
  MAT2 = 1
  CV2 = 1
  CLE = THETA(10)*EXP(ETA(10))*GEN ;Elimination Clearance
  V2 = THETA(11)*EXP(ETA(11)) ;Peripheral Volume
ENDIF

K12 = CLD/V1 ;Calculations of microconstants
K21 = CLD/V2
K10 = CLE/V1
```

**\$DES**


```
IF (AMT.GT.0) THEN ;Obtain and store DOSE for calculation of I
  D = AMT
ENDIF

IF (T.EQ.0) THEN
  I1 = 0
  I2 = 0
ELSE
  FA1= MAT/(6.28*T*T*T*CV*CV) ;Compute absorption rate at TIME
  FA2= FA1**0.5
  FA3= (MAT-T)*(MAT-T)/(2*CV*CV*MAT*T)
  I1 = BIO*D*FA2*EXP(-FA3)
  FA21= MAT2/(6.28*T*T*T*CV2*CV2) ;Compute absorption rate at TIME (second Gauss)
  FA22= FA21**0.5
  FA23= (MAT2-T)*(MAT2-T)/(2*CV2*CV2*MAT2*T)
  I2 = BIO2*D*FA22*EXP(-FA23)
ENDIF

DADT(1) = A(2)*K21 + I1 - (A(1)*K12 + A(1)*K10) ;Central compartment: absorption & recycling
DADT(2) = A(1)*K12 + I2 - A(2)*K21 ;Peripheral compartment
```







	MAT	CV	V1	Q	V2	CLE
SRL	0.73	0.59	20.94	12.54	1531	6.29
CsA	0.73	0.59	20.94	12.54	88.26	9.91



Results presented as a poster at IATDMCT conference in Montreal, Canada, 2009

# Model development

## Comparing Pop-PK to MLR method for AUC prediction



# Therapeutic Drug Monitoring

The laboratory

Slide  
15 / 26



**LEGACY HEALTH SYSTEM AND UNIVERSITY OF PENNSYLVANIA**

This form is to be completed when there are changes to the protocol, or when the study is modified from related studies or additional sites.

**Principal Investigator:** [Redacted]  
**Co-Investigator:** Ahmed Zikri, PharmD

**Title:** *AUC Monitoring of CellCept®*

**THE PROJECT HAS BEEN MODIFIED AS FOLLOWS:**

- Protocol Modification
- Consent Form Modification
- Other (specify): Addition of co-investigator and patient consentor, Ahmed Zikri, PharmD

Does the change affect subject participation (e.g. procedures, risks, costs, etc.)

YES   
NO

If yes, do subjects previously entered need to be notified of major changes?

YES   
NO

**BRIEF SUMMARY OF PROPOSED CHANGE (S) (or attach sponsor's summary):**

This study to date demands the use of brand name CellCept®, as all historical data on which this study is based occurred in an era when generic options for mycophenolate mofetil (MMF) were not in production. Current generic formulations of mycophenolate mofetil have demonstrated

## Fragment of a protocol page

Study done in cooperation between:

- Legacy Health System, Portland, OR, and
- Biomarker Research Lab, University of Pennsylvania, Philadelphia, PA






# AUC Monitoring Study

Overview of study procedures


Slide

17 / 26

**Portland:**



**Philadelphia:**



Less than 24 hours turn-around time

# AUC Monitoring Study

## Data entry

Input worksheet.csv - OpenOffice.org Calc

Plik Edycja Widok Wstaw Format Narzędzia Dane Okno Pomoc

Arial 10 G K P

T24


	A	C	D	F	G	H	I	J	K	L	M	N	O	T	U	V	W	
1	Patient.ID	Visit	Date	Draw.Time.0	Dose.Time	Dose.Amount	Draw.Time.1	Draw.Time.2	Concomitant	Gender	Age	Height	Weight	C0	C40	C120	C240	COMMENT
2	1470821	7	06/29/09	08:58:00 AM	09:00:00 AM	1000	09:45:00 AM	01:15:00 PM	TAC	M	61	182.9	85	1.35	6.82		3.55	
3	2510113	7	07/07/09	08:58:00 AM	09:00:00 AM	1000	09:42:00 AM	01:04:00 PM	TAC	F	58	158.8	63.9	2.14	15.01		1.85	
4	3430421	7	07/07/09	09:10:00 AM	09:15:00 AM	1000	09:55:00 AM	01:15:00 PM	TAC	M	66	188	106.8	0.65	5.81		1.33	
5	4560326	7	07/20/09	08:55:00 AM	09:00:00 AM	1000	09:50:00 AM	01:05:00 PM	TAC	M	53	175.3	117.2	2.79	6.53		2.93	
6	1470821	30	07/28/09	09:00:00 AM	09:00:00 AM	1000	09:40:00 AM	12:55:00 PM	TAC	M	61	182.9	83.6	0.69	0.86		2.98	ate 7:00, dose change
7	2510113	30	07/28/09	09:30:00 AM	09:30:00 AM	1000	10:10:00 AM	01:35:00 PM	TAC	F	58	158.8	59.2	1.87	1.31		11.1	odd PK, dose change,
8	3430421	30	07/28/09	08:30:00 AM	09:00:00 AM	1250	09:10:00 AM	12:30:00 PM	TAC	M	66	188	102.6	3.27	2.76		5.35	odd PK, fasting, incor
9	5501123	7	07/29/09	09:30:00 AM	09:30:00 AM	1000	10:10:00 AM	01:30:00 PM	TAC	F	58	162.6	76.6	4.39	16.6		3.94	dose change
10	6590117	7	07/29/09	08:58:00 AM	09:00:00 AM	1000	09:38:00 AM	01:09:00 PM	TAC	F	50	170.2	87	1.73	15		2.09	
11	4560326	30	08/18/09	09:00:00 AM	09:01:00 AM	1000	09:38:00 AM	01:00:00 PM	TAC	M	53	175.3	118.4	2.33	8.48		8.34	decr 1000 mg bid to 75
12	5501123	30	08/18/09	09:35:00 AM	09:40:00 AM	750	10:15:00 AM	01:30:00 PM	TAC	F	58	162.6	77.5	4.2	12.4		6.98	decr 750 mg bid to 500
13	6590117	30	08/18/09	08:29:00 AM	08:30:00 AM	1000	09:10:00 AM	12:30:00 PM	TAC	F	50	170.2	80.8	6.45	8.24			8 repeat trough (suspect
14	2510113	60	08/24/09	09:27:00 AM	09:30:00 AM	750	10:10:00 AM	01:30:00 PM	TAC	F	58	158.8	63	4.91	40.7		3.39	Decr to 500 mg BID
15	3430421	60	08/24/09	08:57:00 AM	09:00:00 AM	1000	09:43:00 AM	12:58:00 PM	TAC	M	66	188	94.8	1.42	1.06		2.82	Increase to 1250 mg B
16	7531204	7	08/25/09	08:29:00 AM	08:30:00 AM	1000	09:10:00 AM	12:39:00 PM	TAC	M	55	190.5	127.8	1.25	7.39		2.37	FK start 8/24/09; BKA,
17	8620125	7	08/25/09	09:00:00 AM	09:05:00 AM	1000	09:40:00 AM	12:58:00 PM	TAC	M	47	193	93.1	1.1	2.95		1.41	Ince to 1250 mg BID
18	1470821	60	08/31/09	09:35:00 AM	09:40:00 AM	1250	10:15:00 AM	01:32:00 PM	TAC	M	61	182.9	86.1	2.4	13.6		5	
19	6590117	39	08/31/09	09:00:00 AM	12:00:00 AM	1000	12:00:00 AM	12:00:00 AM	TAC	F	50	170.2	80.5	7.59				Trough only verification
20	9470617	7	09/02/09	08:58:00 AM	09:00:00 AM	1500	09:43:00 AM	11:06:00 AM	CSA	M	62	162.6	88.5	2.15	20.2	3.72		
21	10601023	7	09/09/09	08:59:00 AM	09:00:00 AM	1000	09:40:00 AM	01:00:00 PM	TAC	M	48	190.5	90.3	0.52	3.02		0.51	BK viruria, First FK dos
22	11421023	7	09/09/09	08:28:00 AM	08:30:00 AM	1000	09:08:00 AM	12:35:00 PM	TAC	F	66	160	60.7	3.5	3.8		5.33	
23	8620125	30	09/21/09	08:29:00 AM	08:30:00 AM	1250	09:10:00 AM	01:05:00 PM	TAC	M	47	193	90.2	2.61	8.25		3.3	C240 drawn 30 min lat
24	4560326	60	09/21/09	08:55:00 AM	09:00:00 AM	750	09:38:00 AM	12:55:00 PM	TAC	M	53	175.3	120.5					
25																		
26																		
27																		
28																		
29																		



# AUC Monitoring Study


Starting the script

Slide  
19 / 26



# AUC Monitoring Study

Example report page with AUC results



## The click-able batch file

```
"C:\Program Files\R\R-2.9.2\bin\Rterm" --vanilla <"E:\My Documents\Patients\Oregon MPA\Oregon MPA.txt"
```

## The R script

```
# ***** Load data ***** #
ore      = read.csv("E:\\My Documents\\Patients\\Oregon MPA\\Input worksheet.csv")
# ***** Type conversions ***** #
ore$Date = as.Date(as.character(ore$Date), "%m/%d/%y")

for (il in 1:nrow(ore)) {
  ore[il,"DT.1"] = (difftime(strptime(as.character(ore[il,"Dose.Time"]), format= "%I:%M:%S %p"),
    strptime(as.character(ore[il,"Draw.Time.1"]), format= "%I:%M:%S %p")))[1]/(-60)
  ore[il,"DT.2"] = (difftime(strptime(as.character(ore[il,"Dose.Time"]), format= "%I:%M:%S %p"),
    strptime(as.character(ore[il,"Draw.Time.2"]), format= "%I:%M:%S %p")))[1]*(-1)
}

# ***** Calculate MLR AUC ***** #
ore$AUC.mlr = ifelse(toupper(ore$Concomitant)!="CSA", {
  ifelse(is.na(ore$C240),10.19 + 7.15 * ore$C0 + 0.80 * ore$C40 + 2.05 * ore$C120,
    8.31 + 5.91 * ore$C0 + 0.79 * ore$C40 + 5.86 * ore$C240) } ,
  10.43 + 1.47 * ore$C0 + 1.06 * ore$C40 + 1.65 * ore$C120)

ore$AUC.bayes = NA
```

Load the data

Calculate the  
MLR AUC

## NONMEM dataset preparation

```
# ***** Prepare dataset for NONMEM (Model LSS-A6-M8-LOG-AI-S) ***** #  
  
ore.n = matrix(nrow=0, ncol=15)  
for (i1 in 1:nrow(ore)) {  
  ore.c = c(0,ore[i1,"C0"], 0, ore[i1,"C40"], 0, ifelse(is.na(ore[i1,"C120"]),0,ore[i1,"C120"]), 0,  
    ifelse(is.na(ore[i1,"C240"]),0,ore[i1,"C240"]),0,0,0)  
  ore.t = c(0,0,0.33,ore[i1,"DT.1"],1.25,ifelse(is.na(ore[i1,"C120"]),2,ore[i1,"DT.2"]),3,  
    ifelse(is.na(ore[i1,"C240"]),2,ore[i1,"DT.2"]),6,8,12)  
  for (i2 in 1:length(ore.t)) {  
    ore.n = rbind(ore.n, c(paste(trunc(ore[i1,"Patient.ID"]/1000000),ore[i1,"Visit"],sep="."),  
      ore[i1,"Patient.ID"], round(ore.t[i2],3), round(ore.t[i2]+ore[i1,"Visit"]*24,3), ore[i1,"Visit"],  
      ifelse(i2==1, round(ore[i1,"Dose.Amount"]/0.4335/2.306805, 2),0), ifelse(i2==1,1,0),  
      ifelse(i2==1,12,0), ore.c[i2]/0.320/2.306805, ifelse(toupper(ore[i1,"Concomitant"])=="TAC",0,1),  
      ore[i1,"Age"], ore[i1,"Height"], ore[i1,"Weight"], ifelse(ore[i1,"Gender"]=="M",0,1),  
      ifelse(i2==1,1, ifelse(ore.c[i2]==0,2,0))))  
  }  
}
```

Set-up the  
data structure

Followed by setting of column names, sorting, format conversions and log of DV.

## Invoke the NONMEM run

```
# Assign the drive letter K to the working folder and save the data  
system("cmd /c subst K: \"E:\\My Documents\\NONMEM\\")  
write.table(ore.n, "K:/MData/OREGON/DATAFILES/MPAoLOGs.csv", row.names=F, col.names=F, sep="," , dec=".")  
  
# Set working area and execute nonmem - will result in a crash, but output is prepared  
setwd("K:\\MData\\OREGON\\WORKING\\")  
shell("nmfe6 control.LSS-A6-M8-LOG-AI-S.txt output.txt", wait=T, mustWork=NA, ignore.stderr=T)
```

Call to a modified "nmfe6.bat"



## Call the second script

```
source("E:\\My Documents\\Patients\\Oregon MPA\\AUCs.txt", local=F)
```

## Calculate the AUCs from NONMEM simulation results

```
library(caTools)
library(Cairo)
library(plotrix)

# Read file
ore.run = read.table("AllRecords.txt", skip=1, header=T)

# Exponentiate and convert to mg/L
ore.run$eDV = exp(ore.run[, "IPRE"])*0.320
ore.run$eDVT = exp(ore.run[, "DV"])*0.320
ore.run[ore.run$DV==0, "eDVT"] = NA

# Get rid of dosing records and get list of patients
ore.run = ore.run[ore.run$AMT==0,]
ore.ids = unique(ore.run$ID)
ore$IDS = as.numeric(paste(trunc(ore$Patient.ID/1000000), ore$Visit, sep="."))

# Calculate AUCs
for (i1 in 1:length(ore.ids)) ore[ore.ids[i1]==ore$IDS, "AUC.bayes"] =
  round(trapz(ore.run[ore.run$ID==ore.ids[i1], "TIME"], ore.run[ore.run$ID==ore.ids[i1], "eDV"]), 2)
ore$AUC.mlr = round(ore$AUC.mlr, 2)

# Save data table
ore$DT.1 = ore$DT.2 = ore$HPLC = NULL
write.csv(ore, "E:\\My Documents\\Patients\\Oregon MPA\\Output worksheet.csv", row.names=F)
```

This does the  
AUC calculation

### Prepare the report file

```
# Plot the data along with fit
CairoPDF(file = "E:\\My Documents\\Patients\\Oregon MPA\\Report.pdf", width = 8.5/1.3,
height = 11/1.3, onefile = TRUE, title = "R Graphics Output", paper = "letter")

layout(matrix(c(1,1,1,1,1,1,2,2), 4, 2, byrow = TRUE))
for (i1 in 1:length(ore.ids)) {
  dat = ore.run[ore.run$ID==ore.ids[i1],c("TIME","eDV","eDVT")]
  dmax = max(dat[,2:3], na.rm=T)

  plot(dat[,1:2], type="l", xlab= "Time [h]", ylab= "MPA [mg/L]", col= "navyblue",
  lwd=1.5, ylim=c(0, dmax))
  points(ore.run[ore.run$ID==ore.ids[i1],c("TIME","eDVT")], pch=21, bg="#aaff6677",
  cex=1.2)
  text(6, 0.99*dmax, paste( "Patient: ", ore[ore$IDS==ore.ids[i1] ,"Initials"],
  ", Date: ", ore[ore$IDS==ore.ids[i1] ,"Date"], sep=""), adj=c(0.5,0.5), cex=1.3)
  text(10.5, 0.95*dmax, paste(ore[ore$IDS==ore.ids[i1] ,"CNI trough:\n", "Gender:\n", "Age:\n",
  "Height:\n", "Weight:\n"], cex = 1.1, adj=c(1,1))
  text(10.6, 0.95*dmax, paste(ore[ore$IDS==ore.ids[i1] ,"Visit"], "\n",
  ore[ore$IDS==ore.ids[i1] ,"Concomitant"], "\n", ore[ore$IDS==ore.ids[i1] ,
  "CNI.trough"], "\n", ifelse(ore[ore$IDS==ore.ids[i1] ,
  "Gender"]=="M", "Male","Female"), "\n", ore[ore$IDS==ore.ids[i1] ,"Age"],
  " [years]\n", ore[ore$IDS==ore.ids[i1] ,"Height"], " [cm]\n",
  ore[ore$IDS==ore.ids[i1] ,"Weight"], " [kg]\n", ore[ore$IDS==ore.ids[i1] ,"SCr"],
  " [mg/dL]\n", sep = ""), cex = 1.1, adj=c(0,1))
  plot.new()
  a.tab=ore[ore$IDS==ore.ids[i1] ,c("Dose.Amount","C0","C40","C120","C240","AUC.mlr",
  "AUC.bayes")]
  addtable2plot(0,0.5,data.frame(a.tab), xjust=0, yjust=1, hlines=T, cex=1)
  mtext(paste("Comment:\n", ore[ore$IDS==ore.ids[i1] ,"COMMENT"]), side=1, line=0, adj=0, cex=0.5)
}

dev.off()
shell.exec("E:\\My Documents\\Patients\\O
```

Plot simulated profile line

Add raw data points

Add table of results





- ▶ Translate the Pop-PK model to R (*nlmeODE*)
  - ▶ At this stage: able to predict  $C_{\max}$
  - ▶ Poor prediction of  $C_0$  and AUC
  - ▶ Problems with convergence
- ▶ Get rid of NONMEM
- ▶ Add simple GUI
  - ▶ File/folder selection
  - ▶ Model selection, if more than one available



- ▶ University of Pennsylvania (Philadelphia, PA):
  - ▶ Leslie M. Shaw, PhD (laboratory director)
  - ▶ Michał J. Figurski, PhD (project manager)  
contact: [figurski@mail.med.upenn.edu](mailto:figurski@mail.med.upenn.edu)
  - ▶ Leona B. Fields, BSc
  - ▶ Teresa Waligórska, MSc
- ▶ Legacy Health System (Portland, OR)
  - ▶ Ian Doyle, PharmD (PI of the study)
  - ▶ Ahmed Zikri, PharmD
- ▶ Parts of the project (model development) were sponsored by Roche